XDx, Inc.
In: Personalized Medicine (17410541), Jg. 5 (2008-07-01), Heft 4, S. 335-338
academicJournal
Zugriff:
The article provides information on Brisbane, California-based molecular diagnostics company XDx Inc. and discusses the AlloMap® molecular gene expression testing it developed for heart transplant patients. Accordingly, XDx is dedicated to the discovery, development and commercialization of non-invasive gene expression-based testing for the monitoring of transplant rejection and autoimmune disease. It states that AlloMap testing uses a gene expression-based diagnostics to help in the diagnostic of organ rejection caused by immunosuppressive therapy.
Titel: |
XDx, Inc.
|
---|---|
Zeitschrift: | Personalized Medicine (17410541), Jg. 5 (2008-07-01), Heft 4, S. 335-338 |
Veröffentlichung: | 2008 |
Medientyp: | academicJournal |
ISSN: | 1741-0541 (print) |
DOI: | 10.2217/17410541.5.4.335 |
Schlagwort: |
|
Sonstiges: |
|